Stocks Health care FEMY
NASDAQ · Health careFemasys Inc (FEMY)
Femasys Inc brought in $2.3M of revenue over the twelve months to June 30, 2026, up 21.9% from a year earlier. It posted a net loss of $11.8M. In fiscal 2025 capital spending exceeded operating cash flow by $19.2M. At June 30, 2026 it held $1.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Femasys Inc
- Net worth
- Femasys Inc has a market value (market cap) of $12.6M at the latest share price, and shareholders' equity of $4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.3M (+40.8% year on year), with a net loss of $18.6M. Over the 12 months to June 30, 2026: revenue $2.3M, net loss $11.8M.
- Cash flow
- In fiscal 2025 operations used $18.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Femasys Inc's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Femasys Inc does
Femasys Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker FEMY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.3M | -$18.6M | -$0.47 | -$19.2M |
| 2024 | $1.6M | -$18.8M | -$0.85 | -$20.2M |
| 2023 | $1.1M | -$14.2M | -$0.93 | -$11.4M |
| 2022 | $1.2M | -$11.4M | -$0.96 | -$11.1M |
| 2021 | $1.2M | -$7.5M | -$1.12 | -$8.2M |
| 2021 | $1M | -$6.9M | -$7.20 | -$4.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where FEMY ranks in Health care
Latest SEC filings
What Femasys Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 3, 2026
- August 31, 2026Passive stake (5% or more) SCHEDULE 13G
- August 17, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 19% to $331.8K versus the same quarter last year; diluted EPS -$1.33 versus -$3.18.
- August 14, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026
- June 24, 2026
- June 24, 2026Other event 8-K
- June 5, 2026
Insider trades
What the people running Femasys Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Lee-Sepsick KathyChief Executive Officer, Director | Bought | 15,625 | $50K |
| August 7, 2026 | Elefant DovChief Financial Officer | Bought | 15,625 | $50K |
| August 7, 2026 | Canning John CharlesChief Operating Officer | Bought | 4,375 | $14K |
| August 7, 2026 | Sipos Jeremy AlexanderChief Technology Officer | Bought | 3,125 | $10K |
| August 7, 2026 | Mifek Jeffrey GeraldChief Clinical-Medical Affairs | Bought | 3,125 | $10K |
Who owns FEMY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alumni Capital LP13G, passive with 2 related filers | 9.99% | September 4, 2025 |
| Nantahala Capital Partners Limited Partnership13D, may seek influence with 3 related filers | 9.99% | August 17, 2026 |
| Dauntless Investment Group, LLC13G, passive | 9.9% | November 14, 2025 |
| Rosalind Advisors, Inc.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Chernett Jorey13G, passive | 9.3% | August 5, 2025 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 7.2% | August 31, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 41,875 shares in total, about $62.8K at the last price.
| Holder | Shares |
|---|---|
| Elefant DovChief Financial Officer | 15,625 |
| Lee-Sepsick KathyChief Executive Officer, Director | 15,625 |
| Canning John CharlesChief Operating Officer | 4,375 |
| Sipos Jeremy AlexanderChief Technology Officer | 3,125 |
| Mifek Jeffrey GeraldChief Clinical-Medical Affairs | 3,125 |
Questions about FEMY
What does Femasys Inc do?
Femasys Inc is a company in the Health care sector, listed on NASDAQ as FEMY. Its shares trade on NASDAQ under the ticker FEMY.
What is Femasys Inc's net worth?
Femasys Inc has a market value (market cap) of $12.6M at the latest share price, and shareholders' equity of $4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Femasys Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.8M on revenue of $2.3M.
How much revenue does Femasys Inc make?
Over the twelve months to June 30, 2026 Femasys Inc reported revenue of $2.3M. That is 21.9% more than a year earlier.
When did Femasys Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shelf registration to sell securities from September 3, 2026.
When is Femasys Inc's next earnings report?
Femasys Inc's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare FEMY with
Follow FEMY
Get an email when Femasys Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Femasys Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.